Deal includes $1 billion upfront, $300 million for clinical milestones Verve shares surge 75% in early trading Analysts view acquisition as positive for gene-editing sector The companies were ...

Lilly will acquire Verve Therapeutics and a pipeline of one-time treatments for cardiovascular diseases in a deal worth up to US$1.3 billion. "In just seven years, our team has progressed three in ...

An experimental once-daily pill to treat obesity can help people lose a significant amount of weight, according to new data from drugmaker Eli Lilly. The medicine, called orforglipron, belongs to a ...

Patients on Eli Lilly & Co.’s experimental diabetes pill lost more weight and had better blood sugar control than those on an older, approved rival from Novo Nordisk A/S in the first head-to-head ...